Related Experiment Video
Updated: May 30, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
HIV type 1 Gag as a target for antiviral therapy
1Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702-1201, USA. waheedab@mail.nih.gov
Abstract:
The Gag proteins of HIV-1 are central players in virus particle assembly, release, and maturation, and also function in the establishment of a productive infection. Despite their importance throughout the replication cycle, there are currently no approved antiretroviral therapies that target the Gag precursor protein or any of the mature Gag proteins. Recent progress in understanding the structural and cell biology of HIV-1 Gag function has revealed a number of potential Gag-related targets for possible therapeutic intervention. In this review, we summarize our current understanding of HIV-1 Gag and suggest some approaches for the development of novel antiretroviral agents that target Gag.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Size and Structure of Viral Genomes
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release

